psalexa
logo

Constipation Therapeutics – Pipeline Analysis 2017

Constipation Therapeutics – Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Published: December 2017
Report Code: LS11351
Available Format:
Pages: 101

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 By Industry Participant

2.2.2 By Company Type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.1.1 Signs and Symptoms

4.1.2 Pathophysiology

4.1.3 Diagnosis

4.1.4 Treatment

4.1.5 Epidemiology

4.2 Key Drivers

4.8.1 Driver 1

4.8.2 Driver 2

4.3 Key Barrier

4.9.1 Barrier 1

4.4 Constipations Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Constipation Therapeutics Pipeline Analysis by Phase (2017)

5.1 Filed

5.1.1 Elobixibat

5.1.1.1 Clinical trials

5.1.1.2 Clinical results

5.1.1.3 Strategic developments

5.2 Phase III

5.2.1 AJG 555

5.2.1.1 Clinical trials

5.2.1.2 Others

5.2.2 XXXX

5.2.2.1 Clinical trials

5.2.3 XXXX

5.2.3.1 Clinical trials

5.2.3.2 Clinical results

5.2.3.3 Others

5.2.3.4 Technology

5.3 Phase II

5.3.1 BLI 801

5.3.1.1 Clinical trials

5.3.2 XXXX

5.3.2.1 Clinical trials

5.3.3 XXXX

5.3.3.1 Clinical trials

5.3.4 XXXX

5.3.4.1 Strategic developments

5.3.5 XXXX

5.3.5.1 Clinical trials

5.3.5.2 Strategic developments

5.3.6 XXXX

5.3.6.1 Clinical trials

5.3.7 XXXX

5.3.7.1 Clinical trials

5.3.7.2 Clinical results

5.3.8 XXXX

5.3.8.1 Clinical trials

5.3.8.2 Clinical results

5.3.9 XXXX

5.3.9.1 Clinical trials

5.3.9.2 Technology

5.3.10 XXXX

5.3.10.1 Clinical trials

5.3.10.2 Clinical results

5.3.10.3 Strategic developments

5.4 Phase I

5.4.1 NGM 282

5.4.1.1 Clinical trials

5.4.1.2 Strategic developments

5.4.1.3 Technology

5.4.2 XXXX

5.4.2.1 Clinical trials

5.5 Pre-Clinical

5.5.1 XXXX

5.5.1.1 Others

5.5.1.2 Technology

5.5.2 XXXX

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region for Constipation Therapeutics Pipeline

6.2 Clinical Trials by Trial Status for Constipation Therapeutics Pipeline

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Constipation Therapeutics Pipeline

7.2 SWOT Analysis of Constipation Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Nordic Life Science Pipeline Inc.

8.1.1 Business Overview

8.1.2 Pipeline Products

8.2 Enterin Inc.

8.2.1 Business Overview

8.2.2 Pipeline Products

8.3 XXXX

8.3.1 Business Overview

8.3.2 Pipeline Products

8.4 XXXX

8.4.1 Business Overview

8.4.2 Pipeline Products

8.5 XXXX

8.5.1 Business Overview

8.5.2 Pipeline Products

8.6 XXXX

8.6.1 Business Overview

8.6.2 Pipeline Products

8.7 XXXX

8.7.1 Business Overview

8.7.2 Pipeline Products

8.8 XXXX

8.8.1 Business Overview

8.8.2 Pipeline Products

8.9 XXXX

8.9.1 Business Overview

8.9.2 Pipeline Products

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

 

TABLE 1 PIPELINE ANALYSIS OF CONSTIPATION THERAPEUTICS, BY COMPANY (2017)

TABLE 2 DESCRIPTION OF ELOBIXIBAT

TABLE 3 CLINICAL TRIALS OF ELOBIXIBAT

TABLE 4 DESCRIPTION OF AJG 555

TABLE 5 CLINICAL TRIALS OF AJG 555

TABLE 6 DESCRIPTION OF XXXX

TABLE 7 CLINICAL TRIALS OF XXXX

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF BLI 801

TABLE 11 CLINICAL TRIALS OF BLI 801

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 DESCRIPTION OF XXXX

TABLE 15 CLINICAL TRIALS OF XXXX

TABLE 16 DESCRIPTION OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 CLINICAL TRIALS OF XXXX

TABLE 21 DESCRIPTION OF XXXX

TABLE 22 CLINICAL TRIALS OF XXXX

TABLE 23 DESCRIPTION OF XXXX

TABLE 24 CLINICAL TRIALS OF XXXX

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 CLINICAL TRIALS OF XXXX

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 CLINICAL TRIALS OF XXXX

TABLE 29 DESCRIPTION OF NGM 282

TABLE 30 CLINICAL TRIALS OF NGM 282

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 CLINICAL TRIALS OF XXXX

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 NORDIC LIFE SCIENCE PIPELINE INC. - AT A GLANCE

TABLE 36 ENTERIN INC. - AT A GLANCE

TABLE 37 XXXX - AT A GLANCE

TABLE 38 XXXX – AT A GLANCE

TABLE 39 XXXX - AT A GLANCE

TABLE 40 XXXX - AT A GLANCE

TABLE 41 XXXX - AT A GLANCE

TABLE 42 XXXX - AT A GLANCE

TABLE 43 XXXX - AT A GLANCE

 

LIST OF FIGURES

 

FIG 1 RESEARCH METHODOLOGY

FIG 2 SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 5 CONSTIPATION DRUG CANDIDATES UNDER DEVELOPMENT (2017)

FIG 6 CONSTIPATION THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 7 CONSTIPATION THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 8 CLINICAL RESULTS CHART OF XXXX

FIG 9 CLINICAL RESULT OF XXXX

FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 11 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 12 KEY PLAYERS BENCHMARKING

FIG 13 SWOT ANALYSIS

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry